Related Experiment Videos
[Dofetilide to patients with heart failure and left ventricular dysfunction].
C T Torp-Pedersen1, M Møller, P E Bloch-Thomsen
1Kardiologisk afdeling, Odense Universitetshospital.
Ugeskrift for Laeger
|November 30, 2000
Summary
Dofetilide did not reduce mortality in heart failure patients but significantly lowered hospitalizations. It also effectively converted atrial fibrillation to sinus rhythm, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) and left ventricular dysfunction are significant health concerns.
- Class III antiarrhythmic drugs offer potential therapeutic benefits.
Purpose of the Study:
- To evaluate the efficacy of dofetilide in reducing mortality and morbidity in patients with CHF.
- To assess dofetilide's impact on atrial fibrillation conversion and maintenance of sinus rhythm.
Main Methods:
- A double-blind, placebo-controlled study involving 1518 patients with NYHA class III or IV heart failure.
- Dofetilide dosage adjusted for renal function and QT interval; continuous EKG monitoring for three days.
- Minimum one-year follow-up period to assess outcomes.
Main Results:
- Dofetilide did not significantly affect overall mortality rates.
- Hospitalizations for worsening heart failure were significantly reduced (hazard ratio 0.75).
- Dofetilide demonstrated high efficacy in converting atrial fibrillation to sinus rhythm (61% vs. 33% for placebo).
Conclusions:
- Dofetilide is effective for converting and maintaining sinus rhythm in CHF patients with left ventricular dysfunction.
- While not impacting mortality, dofetilide reduces heart failure-related hospitalizations.